Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Vasospastic Angina
2022-502998-42-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat in Coronary vasospasm (CAS) and Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Area under the curve for cutaneous microvascular conductance during acetylcholine iontophoresis and Daily angina episodes. Started Jun 2023; status: completed.
02
Drugs
vericiguat
03
Conditions
Coronary vasospasm (CAS)Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on 2022-502998-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502998-42-00.